OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Subscription & copyright page	276
FBXW10: a male-biased E3 ligase in liver cancer	208
Revumenib: a new era in acute leukemia treatment	167
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Engineering growth factor ligands and receptors for therapeutic innovation	151
Tumor-resident microbes: the new kids on the microenvironment block	142
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	139
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	134
Advisory Board and Contents	131
Subscription & copyright page	122
Subscription and copyright page	118
Radiotherapy and immunotherapy: open questions and future strategies	113
Navigating life as an early career researcher	110
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	106
Engine shutdown: migrastatic strategies and prevention of metastases	103
Accessing the vasculature in cancer: revising an old hallmark	103
Leveraging circulating microbial DNA for early cancer detection	103
Onco-condensates: formation, multi-component organization, and biological functions	103
Benefits and opportunities of the transgenic Oncopig cancer model	102
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	101
Chromatin as an old and new anticancer target	98
Subscription & copyright page	97
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	93
Oncogenic competence: balancing mutations, cellular state, and microenvironment	91
Regulation of metastatic organotropism	91

Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	88
Crosstalk of T cells within the ovarian cancer microenvironment	85
Recent developments in myeloid immune modulation in cancer therapy	84
Diet, nutrient supply, and tumor immune responses	80
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	77
Chromosomal instability and aneuploidy as causes of cancer drug resistance	74
Advisory Board and Contents	73
Gut microbiota – a double-edged sword in cancer immunotherapy	73
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	66
Tumor immunology CRISPR screening: present, past, and future	64
GOT2 consider the tumor microenvironment	62
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	62
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	62
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	61
Pannexin biology and emerging linkages to cancer	60
Cell death, therapeutics, and the immune response in cancer	60
Subscription & copyright page	59
Subscription & copyright page	58
Advisory Board and Contents	56
Advisory Board and Contents	56
β-Galactosylceramidase in cancer: friend or foe?	55
Scaling data toward pan-cancer foundation models	54
Palmitate paves the way to lung metastasis	53
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	53
Insights on ErbB glycosylation – contributions to precision oncology	52
Genetic immune escape in cancer: timing and implications for treatment	52
Cancer catecholamine conundrum	52